RxDoctor Payments Data

Perry Fleisher, MD

Interventional Cardiology · Cleveland, OHNPI 1992704324

Payments from drug & device makers

$1,757in general payments, 2019–2025

Across 78 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$549
  • Kestra Medical Technology Services, Inc.$344
  • Amgen$336
  • Novartis$249
  • Boehringer Ingelheim$65
  • E.r. Squibb & Sons, L.L.C.$60
  • plus $153 from 8 others

What the payments were for

  • Travel & lodging$19211%
  • Food & beverage$1,56589%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,757 in reported general payments places this provider in the 25th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$141,395
Medicare patients
958
Services billed
2,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban494$464,687
Repatha SureclickEvolocumab77$83,059
XareltoRivaroxaban62$78,993
EntrestoSacubitril/Valsartan21$38,708
JardianceEmpagliflozin25$24,599
Praluent PenAlirocumab23$14,926
Metoprolol Succinate477$6,029
Rosuvastatin Calcium356$4,443
Flecainide Acetate78$3,047
Nifedipine ErNifedipine102$2,623
Atorvastatin Calcium375$2,499
Dofetilide31$2,412
Diltiazem 24hr Er (Cd)Diltiazem Hcl71$2,201
Carvedilol319$2,138
Ezetimibe67$1,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$464,687494 claims
NovartisEntresto$249$38,70821 claims
Boehringer IngelheimJardiance$65$24,59925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →